2021
DOI: 10.1080/03007995.2021.2007006
|View full text |Cite
|
Sign up to set email alerts
|

Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
2
1

Relationship

1
5

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 60 publications
2
4
0
Order By: Relevance
“…In addition, no significant changes in body weight and BMI were observed at 24 weeks. This finding et al 22 but was consistent with another study. 23 In Emond et al's study, patient weight changes were statistically significant only at 36 weeks.…”
Section: (B) (A)supporting
confidence: 90%
“…In addition, no significant changes in body weight and BMI were observed at 24 weeks. This finding et al 22 but was consistent with another study. 23 In Emond et al's study, patient weight changes were statistically significant only at 36 weeks.…”
Section: (B) (A)supporting
confidence: 90%
“…In addition, no signi cant changes in body weight and BMI were observed at 24 weeks. This nding contradicted Emond et al [22] but was consistent with another study [23]. In Emond et al's study, patient weight changes were statistically signi cant only at 36 weeks.…”
Section: Discussionsupporting
confidence: 57%
“…Research on the consequence of ART use on cardiometabolic outcomes has started to emerge recently [11,[27][28][29][30][31], owing to growing evidence on the association of some ART with weight gain [7][8][9][32][33][34][35]. In a US analysis of INSTI-associated metabolic changes in virally controlled women enrolled in the longitudinal Women's Interagency HIV Study (WIHS), PLWH who switched to or added an INSTI to their ART regimen had significant increases in HbA1c and blood pressure relative to those who remained on a non-INSTI ART regimen after a median follow-up of approximately 2 years [11].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, obesity and elevated body mass index (BMI) are well‐established risk factors for cardiometabolic disease [ 45 , 46 ], and significantly greater weight/BMI increases have been reported among PLWH treated with INSTI versus non‐INSTI regimens [ 9 , 32 , 35 ]. These observations may have important clinical implications for PLWH, as it has been shown that weight gain conferred an even greater risk of incident diabetes mellitus among PLWH than among HIV‐negative individuals [ 47 ].…”
Section: Discussionmentioning
confidence: 99%